Le Lézard
Classified in: Health, Covid-19 virus
Subjects: LEG, DIS, AVO

Prevent Blindness to Hold Sixteenth Annual "Eyes on Capitol Hill" Advocacy Event


CHICAGO, Feb. 10, 2021 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's oldest non-profit eye health organization, will be holding its sixteenth annual "Eyes on Capitol Hill" advocacy event, held virtually this year, on Wed., Feb. 24 and Thurs., Feb. 25, 2021. The program brings together patients, caregivers, public health workers, and medical professionals with their elected officials to educate lawmakers and their staff on vision issues, including equitable access to quality eyecare, health disparities in the prevalence of vision disorders, and the importance of sight-saving research and surveillance.

The event also provides an important opportunity to reach out to newly elected members of Congress to introduce them to critical vision advocacy initiatives. As learned during the Coronavirus pandemic, many of the circumstances that surround vision loss and eye disease?such as age, presence of chronic disease, and health disparities?intersect with COVID-19 and its most serious consequences, underscoring the need for advocacy to ensure that public policy accounts for those who live with blinding eye diseases.

In addition to sharing their personal stories of the importance of healthy vision, this year's Eyes on Capitol Hill advocates will ask elected officials to:

"From its founding in 1908, Prevent Blindness has continued to be, at its core, a public health advocacy organization," said Jeff Todd, president and CEO of Prevent Blindness. "By working to give those who are directly affected by vision issues the opportunity to educate our government representatives directly on the importance of eye health, the Eyes on Capitol Hill event continues to carry on that mission."

For more information on Eyes on Capitol Hill, or Prevent Blindness and its advocacy initiatives, please call (800) 331-2020 or visit https://preventblindness.org/advocacy-initiatives/.

About Prevent Blindness
Founded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, visit us at preventblindness.org, and follow us on Facebook, Twitter, Instagram and LinkedIn.

###

Media Contact

Sarah Hecker, Prevent Blindness, 312.363.6035, [email protected]

Twitter

 

SOURCE Prevent Blindness


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: